Go homepage(回首页) Upload pictures (上传图片) Write articles (发文字帖)
The author:(作者)aaapublished in(发表于) 2013/12/18 10:04:33 Shanghai pharmaceutical in response to a complaint of bribery： zero tolerance for violations of law and discipline
Shanghai December 17, Reuters new media ("Site," journalist Gong Wen Zhou Lin Zhu 翃) 17th media reports, Shanghai pharmaceutical group, Inc (hereinafter referred to as Shanghai Pharma) has been reported to 31 hospitals in Qingdao in China and bribing. In this regard, Shanghai pharmaceutical, through its public relations firm told Xinhua "Site in China," Xinhua said in a statement, violations of "zero tolerance". Current Qingdao, there was no concrete response.
According to media reports, a focus of the Shanghai pharmaceutical medicines "red source" to 31 hospitals in Qingdao in China and bribing, 2013-June amounted to alleged improper trading of 766,500 Yuan spending to correspond to sales revenues of over 26%.
Reporters from the State food and Drug Administration website to, trade names as "red source of" common names "polysaccharide-iron complex capsules", produced by Qingdao Guofeng pharmaceutical company limited.
17th, the Shanghai pharmaceutical, through his public relations firm said in a statement, the company has always been for any violations of law and discipline has always been to firmly put an end to the zero-tolerance attitude, on the issue of violations of a clean and honest Government has, once verified, in accordance with the relevant State laws and regulations and the company of the honest implementation of the accountability system, such as implementation of the responsibility system, and to take all the necessary measures. Also attached great importance to the matters raised in the various media reports and consistent compliance with the legal and moral obligation to start the verification process.
In addition, the Shanghai pharmaceutical headquarters and affiliated companies have established rigorous internal control system, and signed with the core subsidiary of the clean government responsibility, focusing on clean and ask tough questions of management. Group this year were issued to subordinate units of the notice on further standardizing operation activities and to reaffirm unequivocally forbidden to seek or offer improper advantages.
In addition, the Shanghai pharmaceutical education staff adhere to pharmaceutical promotion code of conduct requires Enterprise sales compliance for pharmaceutical sales activities according to the law.
It is understood that the Shanghai Pharma owns 67.52% shares of wind in Qingdao. One Qingdao Guofeng senior leaders (former Chairman of Qingdao Guofeng Chen Junli) in an interview with Xinhua, said, this drug as nonprescription drugs, most of them in the hospital sales, sales have been pretty good. But asked about bribery in hospitals, he said cautiously that he had transferred to other companies, and why they respond.
Journalists at 11 o'clock in the morning to Shanghai pharmaceutical Secretary interview outline to text message, his Secretary reply "thank you" remains unanswered after State, whose President is said by the Secretary of the Board contact reporters. However, as of press time, Secretary of the Board does not again contact reporters, telephone also remains unanswered.
31 hospitals in Qingdao, and the ancestors of regulators so far have not explicitly respond to.
A Netizen named "daze of sunflowers," says: "now any plant not by giving doctors kickbacks to boost sales? This is only the iceberg. Related units and hospitals are not involved in the investigation in a timely manner and respond positively, secretive than this is a guilty conscience. "Friends" 1314 "says:" increasingly, drug competition to ensure that sales number, product development in the hospital, you need to open up the upper and lower levels of the hospital. Give doctors kickbacks in disguise, finally to put all costs to the patient on the patient's head. ”
United Kingdom pharmaceutical giant Glaxo SmithKline China's economic crime investigation, several drug firms being investigated so far this year, commercial bribery in medical field as "no time bombs" explode one after another. Whether it will lead to the whole industry, "end" and liquidation, has become the industry's speculation.
One industry analyst said, drug companies increase sales by bribing hospital, doctors are already in the industry, "open secret", investors have also been "flattering", which in part for many companies to get away with the "bottom line" – unless the Government took the matter to "axe", not for the entire industry "shock wave".
A Netizen named "OS with no flowers," said: "drug firms do not bribe, what to sell drugs to public hospitals? Do not address the root causes of issues from health care reform, a red source goes down, thousands of tiny red source to stand up, and women struggled and teeming. ”
新华网上海12月17日新媒体专电 (“中国网事”记者龚雯 周琳 朱翃)17日有媒体报道，上海医药集团股份有限公司(以下简称上海医药)被举报在青岛市内向31所医院和从业人员行贿。对此，上海医药通过其公关公司向新华社“中国网事”记者发布声明称，对违法违纪行为“零容忍”。而目前青岛方面尚无具体回应。
根据媒体的报道，上海医药的一款重点药品“红源达”在青岛市内向31所医院和从业人员行贿，2013年1－6月份共计76.65万元涉嫌不当交易的支出，占到相对应销售收入的26%以上。
记者从国家食品药品监督管理总局网站上查询到，商品名为“红源达”的通用名为“多糖铁复合物胶囊”，由青岛国风药业股份有限公司生产。
17日，上海医药通过其公关公司声明称，公司一直以来对于任何违法违纪的行为始终抱以坚决杜绝的零容忍态度，对已发生的违反廉政建设问题的情况，一经查实将按照国家相关法律法规和公司《党风廉政建设责任制实施意见》等制度实施责任追究，并采取一切必要的措施。同时也一直非常重视各类媒体报道中提出的事宜，并以一贯遵守法律和道德义务的态度启动相应核实工作程序。
另外，上海医药本部及下属企业均建立了严谨的内部监控体系，并每年与核心子公司签订《廉政建设责任书》，重点对于经营管理的廉洁提出严格要求。今年集团公司更是向下属单位下发了《关于进一步规范经营行为的通知》，明确重申严禁谋取或提供不正当利益。
此外，上海医药将教育员工恪守药品推广行为准则，要求企业销售人员依法合规进行药品销售活动。
据了解，上海医药持有青岛国风67.52%的股份。一位原青岛国风高层领导(原青岛国风董事长陈军力)在接受记者采访时称，这个药作为非处方药，大部分都在医院销售，销量一直都挺不错。但问及医院贿赂一事，他谨慎地说自己已经调往其他企业任职，所以不便回应。
记者上午11时向上海医药董秘短信发去采访提纲，其董秘回复“谢谢关心”后就一直处于无人接听状态，其总裁则称将由董秘联系记者。但截至发稿，董秘并未再次主动联系记者，电话也一直处于无人接听状态。
青岛31家医院及其上级监管部门截至目前仍未就此明确回应。
网友“发呆的向日葵”说：“现在哪家药厂不是靠给医生回扣来提升销量？这只是冰山一角罢了。相关单位和医院不及时介入调查并正面回应，遮遮掩掩只能说明是心虚。”网友“晓看1314”说：“现如今，药品竞争激烈，要保证销售数量，让产品开发进医院，需要打通医院上下各级关系。变相地给医生回扣，最终还是要把全部费用转嫁到病人患者头上。”
从英国制药巨头葛兰素史克在中国因经济犯罪被立案调查，到多家药企被调查，今年以来，医药领域的商业贿赂事件如同“不定时炸弹”，接二连三爆炸。是否会引发对整个行业的“起底”和清算，也成为业界的猜测。
一位行业分析人士表示，药企通过行贿医院、医生提高销量已经是业内“公开的秘密”，投资者也已经“见怪不怪”，这在一定程度上给不少企业侥幸的心理“底线”——除非政府拿这个事情来“开刀”，否则不会对整个行业造成“冲击波”。
正如网友“OS无花”说：“药企不行贿，怎么向这些公立的医院卖药？ 不从医疗改革的根源上解决问题，一个红源达倒下去，千千万万个红源达站起来，前赴后继，生生不息。”
赞